For: | Mella A, Gallo E, Messina M, Caorsi C, Amoroso A, Gontero P, Verri A, Maletta F, Barreca A, Fop F, Biancone L. Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results. World J Transplantation 2018; 8(5): 178-187 [PMID: 30211026 DOI: 10.5500/wjt.v8.i5.178] |
---|---|
URL: | https://www.wjgnet.com/2220-3230/full/v8/i5/178.htm |
Number | Citing Articles |
1 |
Shima Afzali, Saeedeh Salehi, Abbas Shahi, Aliakbar Amirzargar. B cell modulation strategies in the improvement of transplantation outcomes. Molecular Immunology 2020; 125: 140 doi: 10.1016/j.molimm.2020.06.028
|
2 |
Yi-bo Hou, Sheng Chang, Song Chen, Wei-jie Zhang. Intravenous immunoglobulin in kidney transplantation: Mechanisms of action, clinical applications, adverse effects, and hyperimmune globulin. Clinical Immunology 2023; 256: 109782 doi: 10.1016/j.clim.2023.109782
|
3 |
Enrique Montagud‐Marrahi, Ignacio Revuelta, David Cucchiari, Gaston J. Piñeiro, Pedro Ventura‐Aguiar, Miquel Lozano, Joan Cid, Jaume Martorell, Manel Solé, Luis F. Quintana, Federico Oppenheimer, Fritz Diekmann, Esteban Poch, Josep M. Campistol, Miquel Blasco. Successful use of nonantigen‐specific immunoadsorption with antihuman Ig‐columns in kidney graft antibody‐mediated rejection. Journal of Clinical Apheresis 2020; 35(3): 188 doi: 10.1002/jca.21779
|
4 |
Kavitha Muralidharan, Divyansh Agarwal, Ali Naji, Vijay G. Bhoj. Therapeutic Opportunities for Immunoreceptor-Engineered T Cell Therapy for Modulation of Alloimmunity. The Journal of Immunology 2022; 209(10): 1811 doi: 10.4049/jimmunol.2200542
|
5 |
A. Brand, V. De Angelis, T. Vuk, O. Garraud, M. Lozano, D. Politis. Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand. Transfusion Clinique et Biologique 2021; 28(1): 96 doi: 10.1016/j.tracli.2020.12.005
|
6 |
Michiel G.H. Betjes, Marcia M.L. Kho, Nicolle H.R. Litjens, Annelies E. de Weerd, Joke I. Roodnat. Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys. Transplantation Proceedings 2021; 53(7): 2206 doi: 10.1016/j.transproceed.2021.07.005
|
7 |
Alessandro Gambella, Antonella Barreca, Simona Osella-Abate, Emanuel Bottasso, Manuela Maria Giarin, Mauro Papotti, Luigi Biancone, Jasna Metovic, Giammarco Collemi, Paola Cassoni, Luca Bertero. Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel. Biomedicines 2021; 9(10): 1318 doi: 10.3390/biomedicines9101318
|
8 |
Kin Yee Shiu, Dominic Stringer, Laura McLaughlin, Olivia Shaw, Paul Brookes, Hannah Burton, Hannah Wilkinson, Harriet Douthwaite, Tjir-Li Tsui, Adam Mclean, Rachel Hilton, Sian Griffin, Colin Geddes, Simon Ball, Richard Baker, Candice Roufosse, Catherine Horsfield, Anthony Dorling. Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.00079
|
9 |
Antonio Lavacca, Roberto Presta, Chiara Gai, Alberto Mella, Ester Gallo, Giovanni Camussi, Isabella Abbasciano, Antonella Barreca, Cristiana Caorsi, Fabrizio Fop, Maria Messina, Maura Rossetti, Luigi Biancone. Early effects of first‐line treatment with anti‐interleukin‐6 receptor antibody tocilizumab for chronic active antibody‐mediated rejection in kidney transplantation. Clinical Transplantation 2020; 34(8) doi: 10.1111/ctr.13908
|
10 |
Kasia A. Sablik, Marian C. Clahsen- van Groningen, Jeffrey Damman, Dave L. Roelen, Michiel G.H. Betjes. Banff lesions and renal allograft survival in chronic-active antibody mediated rejection. Transplant Immunology 2019; 56: 101213 doi: 10.1016/j.trim.2019.101213
|
11 |
Yi-Yuan Chen, Xin Sun, Wei Huang, Fang-Fang He, Chun Zhang. Therapeutic apheresis in kidney diseases: an updated review. Renal Failure 2022; 44(1): 842 doi: 10.1080/0886022X.2022.2073892
|